DELIVER NEW
TREATMENTS

Tackling cancer by leveraging multiple modalities

Our oncology programs encompass multiple modalities, including a PD-1 x VEGF bispecific antibody that we see as a foundational backbone, as well as antibody-drug conjugates (ADCs) that could be utilized either alone or in combination with our immunotherapy candidate. We’re working smartly and efficiently by leveraging established targets and validated biology, with the goal of advancing rapidly towards multiple solid tumor indications.

Programs with potential for monotherapy or combination therapy across multiple solid tumor indications
PROGRAM
MOA
DISCOVERY
IND-ENABLING
CLINICAL
POTENTIAL
INDICATIONS
DEVELOPMENT
REGION
CR-001
CLINICAL
PD-1 x VEGF
Same cooperative MOA as ivonescimab
 
NSCLC,
other solid
tumors
logo global sign Global
(Ex-China)
logo biotech sign Greater China
CR-002
IND-ENABLING
PD-L1 ADC
ADC with Topoli payload
Solid
tumors
logo global sign Global
CR-003
(SKB105)
CLINICAL
ITGB6 ADC
ADC with Topoli payload
 
Solid
tumors
logo global sign Global
(Ex-China)
logo biotech sign Greater China
CR-004
DISCOVERY
Undisclosed
Undisclosed ADC
 
Solid
tumors
logo global sign Global
NSCLC: Non-small cell lung cancer. MoA: Mechanism of action. ADC: Antibody-drug conjugates.
Topoli: Topoisomerase 1 inhibitor; Ex-China refers to Ex-Greater China.
logo Crescent logo biotech

CR-001

A cooperative tetravalent
bispecific antibody with the same
MOA as ivonescimab

Our lead program, CR-001, is a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors. We are focused on potential first-in-class and fast follower opportunities with a rapid path to market and high probability of success based on clinical validation from approved VEGF and PD-(L)1 therapies.

CR-001 has been intentionally designed to exhibit the cooperative pharmacology of ivonescimab, another tetravalent PD-1 x VEGF bispecific antibody that has demonstrated superior efficacy vs market-leading pembrolizumab in a large, third-party Phase 3 clinical trial.1 CR-001’s PD-1 checkpoint inhibition is aimed at restoring T cells’ ability to recognize and destroy tumor cells. Its structure may also promote localization of anti-VEGF activity into the tumor microenvironment, potentially helping to concentrate therapeutic exposure within the tumor and limit systemic exposure. CR-001 may also normalize the vasculature at the tumor site, which has the potential to improve the localization and effectiveness of combination therapies, making CR-001 a potential backbone of future combination regimens, such as the administration of CR-001 with antibody-drug conjugates (ADCs). A global Phase 1/2 trial of CR-001 in patients with solid tumors is anticipated to initiate in the first quarter of 2026.

Novel, cooperative PD-1 x VEGF MOA may drive enhanced anti-tumor activity while maintaining tolerability
Tumor targeting
  • Dual blockade of PD-1 and VEGF through a novel tetravalent bispecific format with cooperative binding effects has led to unprecedented clinical results in third-party trials
  • PD-1 arm concentrates VEGF inhibition in the TME, potentially sparing healthy tissue and reducing AEs
Cooperativity
  • The cooperative binding with an agent such as CR-001 may block PD-1/PD-L1 interactions and inhibit VEGF
  • VEGF binding to an agent like CR-001 may increase affinity to PD-1 and vice versa, enhancing both T cell activation and VEGF signaling blockade
  • PD-1 binding strength (affinity) is increased in the presence of VEGF

Reference: 1. Xiong A et al. Lancet. 2025;405(10481):839–849.

Potentially best-in-class ADCs with topoisomerase inhibitor payloads

CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

CR-002

topoisomerase inhibitor
ADC targeting PD-L1

CR-002 is a topoisomerase inhibitor ADC directed to PD-L1, a validated target known to have high expression in multiple solid tumors. CR-002 incorporates a PD-L1 antibody selected for high internalization to facilitate payload release in target cells and a linker designed for intracellular cleavage and high stability in circulation. Crescent plans to submit an IND to the U.S. Food and Drug Administration for CR-002 in mid-2026 to support the initiation of a Phase 1/2 trial in solid tumors in the second half of 2026.

CR-003 (SKB105)

topoisomerase inhibitor ADC
targeting Integrin beta-6

CR-003 (also known as SKB105) is a differentiated ADC targeting integrin beta-6 (ITGB6) with a topoisomerase 1 inhibitor payload. ITGB6 is overexpressed in many solid 
tumors, but shows minimal to no expression in most normal tissues, thereby potentially reducing the risk of systemic 
toxicity and off-target effects. CR-003 consists of an anti-ITGB6 fully human IgG1 monoclonal antibody conjugated via a stable, clinically validated cleavable linker. The molecule incorporates proprietary Kthiol® irreversible conjugation technology, designed to enhance stability and tumor-specific payload delivery while reducing adverse effects. CR-003 demonstrated 
a favorable efficacy, safety, and pharmacokinetic (PK) profile in preclinical models. A Phase 1/2 clinical trial of CR-003 in patients with solid tumors is anticipated to commence in the first quarter of 2026.

Pipeline Expansion Opportunities

Crescent also plans to continue to pursue opportunities to advance its strategy in immuno-oncology and best-in-class ADC combinations through internal efforts and with leading partners, including Kelun-Biotech and Paragon Therapeutics.

Presentations & Publications

November 7, 2025
Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Preclinical development of CR-001, a novel tetravalent PD-1 x VEGF bispecific antibody with cooperative pharmacology and potent anti-tumor activity